– USA, ME – ImmuCell Corporation (Nasdaq:ICCC), a growing animal health company that develops, manufactures and markets scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle, today announced that Mr. Steven T. Rosgen and Ms. Bobbi Jo Brockmann were appointed to its Board of Directors effective immediately.
Mr. Rosgen, based in Calgary, Alberta, Canada, has more than 28 years of experience building brand strategies for products, services and organizations in a range of industries including working with leading global agricultural brands. Currently, he is President of Strategem Research Inc., a company he founded in 2005 to integrate consumer insights into clients’ pricing and branding strategies. Previously, he was a senior partner with Street Smart Strategic Planning. He holds a Bachelor of Commerce Degree from the University of Calgary.
“I’m pleased to be appointed to the Board of Directors of ImmuCell at a time when the Company is introducing major new technologies for livestock producers. As a marketer there is nothing more exciting than the chance to disrupt markets with innovative products,” said Mr. Rosgen. “In my role as a board member, I look forward to helping align the Company’s core competencies with market needs to drive customer satisfaction and stockholder value.”
In addition to her appointment to the board, Ms. Brockmann will continue to serve the Company as Vice President of Sales and Marketing. She first joined ImmuCell as Director of Sales and Marketing in 2010. “Our portfolio is expanding with one-of-a-kind products that can provide meaningful economic benefit to dairy and beef producers. That’s something that I’m excited to be a part of,” added Ms. Brockmann. “I look forward to increasing my contribution to ImmuCell as a member of the board.”
“We recently launched First Defense® Tri-Shield™, the only USDA approved calf-level scours preventative providing immediate immunity against E. coli, coronavirus, and rotavirus pathogens, and we are fast approaching the anticipated launch of our intramammary treatment for subclinical mastitis, which will not require a milk discard,” commented Michael F. Brigham, President and CEO. “Expanding the sales and marketing expertise of our board will help us execute our growth plan.”
The Company’s Board of Directors is now comprised of four independent directors and three non-independent directors. All directors are subject to re-election by the Company’s stockholders at the 2018 Annual Meeting of Stockholders.
ImmuCell Corporation’s (Nasdaq:ICCC) purpose is to create scientifically-proven and practical products that improve the health and productivity of dairy and beef cattle. ImmuCell has developed products that provide significant, immediate immunity to newborn dairy and beef livestock. The Company is developing a novel treatment for mastitis, the most significant cause of economic loss to the dairy industry.
For more information : http://www.immucell.com
- Disclaimer - News, data and statement included in this release are intended exclusively for general information purposes. Talent4Boards accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the adequacy or accuracy of the information. No data or statement in this release should be considered for decisions about securities referred. Product and brand names used in this release maybe trademarks or registered trademarks of their respective owners.
Comments are closed.